Filter by Year:
Press Releases
-
Feb 28, 2022
Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference
-
Jan 10, 2022
Foghorn Therapeutics Announces Chief Scientific Officer Succession
-
Jan 07, 2022
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference
-
Dec 13, 2021
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform
-
Nov 11, 2021
Foghorn Therapeutics to Participate at the 2021 Jefferies London Healthcare Conference
-
Nov 09, 2021
Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update
-
Oct 19, 2021
Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit
-
Sep 01, 2021
Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
-
Aug 23, 2021
Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609
-
Aug 10, 2021
Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update
Displaying 31 - 40 of 58